| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| encorafenib and binimetinib melanoma | 1.72 | 0.3 | 1382 | 18 | 36 |
| encorafenib | 1.21 | 0.2 | 6922 | 57 | 11 |
| and | 0.14 | 0.3 | 5377 | 94 | 3 |
| binimetinib | 0.82 | 0.5 | 6868 | 21 | 11 |
| melanoma | 1.7 | 0.8 | 4613 | 6 | 8 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| encorafenib and binimetinib melanoma | 1.91 | 0.4 | 6493 | 5 |
| encorafenib binimetinib melanoma | 0.66 | 0.1 | 9902 | 17 |
| encorafenib + binimetinib | 0.26 | 0.6 | 7783 | 10 |
| encorafenib and binimetinib side effects | 1.06 | 0.6 | 5074 | 67 |
| encorafenib and binimetinib nccp | 1.09 | 0.3 | 4008 | 55 |
| encorafenib and binimetinib spc | 0.34 | 0.3 | 1881 | 77 |
| dabrafenib and trametinib melanoma | 1.29 | 0.6 | 9960 | 32 |
| encorafenib and cetuximab macmillan | 0.44 | 0.6 | 1954 | 28 |
| cetuximab and encorafenib protocol | 0.57 | 0.9 | 8877 | 10 |
| dabrafenib trametinib adjuvant melanoma | 0.12 | 0.3 | 3877 | 79 |
| encorafenib panitumumab colon cancer | 1.64 | 0.4 | 7864 | 71 |
| encorafenib in combination with cetuximab | 0.9 | 0.8 | 5249 | 52 |
